1. |
Estrogen and Alzheimer's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Enoxaparin sodium yields savings for outpatients in the US |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Ruboxistaurin provides hope in diabetic peripheral neuropathy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 7-8
Ngaire White,
Preview
|
|
摘要:
The protein kinase C inhibitor ruboxistaurin [LY 333531] improves symptomatic diabetic peripheral neuropathy, according to results from a phase II study presented at the 62nd Scientific Sessions of the American Diabetes Association (ADA) [San Francisco, US; June 2002]. Nerve function and sensory symptoms were significantly improved in ruboxistaurin recipients in this placebo-controlled study.'We are very encouraged to see important early results for LY 333531 in diabetic peripheral neuropathy after only one year',said Dr Skip Vignati, medical director for protein kinase C inhibitor research at Eli Lilly.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Darbepoetin-α effective for anaemia in haemodialysis patients |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
Ziprasidone superior to haloperidol in schizophrenia |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Finasteride plus doxazosin combination tops in BPH |
|
Inpharma Weekly,
Volume &NA;,
Issue 1351,
2002,
Page 11-12
Ed Susman,
Preview
|
|
摘要:
Combination therapy with the 5-α reductase inhibitor finasteride ['Proscar'] plus the α1receptor blocker doxazosin ['Cardura'] is more effective in slowing the progression of benign prostatic hyperplasia (BPH) than treatment with either agent alone, according to results from the MTOPS*study presented at the 97th Annual Meeting of the American Urological Association (AUA) [Orlando, US; May 2002]. Significant improvements in all BPH symptoms evaluated, and reductions in the risk of disease progression, were observed in patients treated with the combination therapy, compared with placebo recipients. However, only finasteride monotherapy was shown to significantly reduce the risk of prostate cancer.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|